Grundlagen und Stellenwert der COMT- und MAO-B-Inhibitoren in der Therapie des idiopathischen Parkinson-Syndroms

Translated title of the contribution: The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease

Dirk Woitalla*, Rejko Krüger, Stefan Lorenzl, Thomas Müller, Guenther Oelwein, Alexander Storch, Martin Wolz, Ullrich Wüllner

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Inhibitors of COMT and MAO-B are well established in the pharmacotherapy of Parkinson's disease (PD). MAO-B inhibitors are used as monotherapy as well as in combination with levodopa, whereas COMT inhibitors exert their effects only in conjungtion with levodopa. Both classes of compounds prolong the response duration of levodopa and optimise its clinical benefit. As a result, the ON-times are prolonged significantly. In the past, MAO-B inhibitors were also adminstered for neuroprotection; however, despite convincing scientific reasoning in support of neuroprotective effects, these could not be substantiated in clinical studies performed so far.

Translated title of the contributionThe role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease
Original languageGerman
Pages (from-to)620-633
Number of pages14
JournalFortschritte der Neurologie Psychiatrie
Volume88
Issue number9
DOIs
Publication statusPublished - 1 Sep 2020
Externally publishedYes

Keywords

  • COMT inhibitor
  • Idiopathic Parkinson Syndrome
  • MAO inhibitor
  • Metabolisation
  • Review
  • Therapy

Fingerprint

Dive into the research topics of 'The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease'. Together they form a unique fingerprint.

Cite this